Gross Profit Analysis: Comparing Zoetis Inc. and Ligand Pharmaceuticals Incorporated

Zoetis vs. Ligand: A Decade of Gross Profit Trends

__timestampLigand Pharmaceuticals IncorporatedZoetis Inc.
Wednesday, January 1, 2014554020003068000000
Thursday, January 1, 2015661070003027000000
Friday, January 1, 20161034020003222000000
Sunday, January 1, 20171357360003532000000
Monday, January 1, 20182451160003914000000
Tuesday, January 1, 20191089350004268000000
Wednesday, January 1, 20201560000004618000000
Friday, January 1, 20212149570005473000000
Saturday, January 1, 20221434180005626000000
Sunday, January 1, 2023962650005834000000
Monday, January 1, 20246537000000
Loading chart...

Unleashing the power of data

Gross Profit Trends: Zoetis Inc. vs. Ligand Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis compares the gross profit trends of Zoetis Inc. and Ligand Pharmaceuticals from 2014 to 2023. Over this period, Zoetis Inc. consistently outperformed Ligand Pharmaceuticals, with its gross profit growing by approximately 90%, reaching a peak in 2023. In contrast, Ligand Pharmaceuticals experienced more volatility, with a notable peak in 2018, followed by fluctuations. By 2023, Zoetis Inc.'s gross profit was nearly 60 times that of Ligand Pharmaceuticals, highlighting its dominant market position. This disparity underscores the importance of strategic positioning and operational efficiency in the pharmaceutical sector. As the industry continues to innovate, these financial insights provide a lens into the competitive dynamics shaping the future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025